Teva launches generic Lovenox and Zyvox in US

The injection is indicated for prophylaxis of deep vein thrombosis (DVT) in patients undergoing abdominal surgery, hip or knee replacement surgery, or in medical patients with severely restricted mobility during acute illness; and also to treat acute DVT.

Earlier, Teva had entered into a licensing agreement with Chemi SPA to use its internal research based technology to develop and manufacture enoxaparin sodium injection, USP.

Recently, the company has also launched the generic equivalent to Zyvox (linezolid) Injection which is used to treat infections caused by Gram-positive bacteria.

Infections caused by susceptible Gram-positive bacteria include nosocomial pneumonia; Community-acquired pneumonia; Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis; Uncomplicated skin and skin structure infections; and Vancomycin-resistant Enterococcus faecium infections.

Teva Global Generic Medicines president and CEO Siggi Olafsson said: "Teva is committed and focused on building a stronger generic injectable business globally.

"With the launch of Enoxaparin Sodium Injection, USP and Linezolid Injection, accompanied by the reintroduction of three generic injectable products, we are leveraging the strength of our internal and external resources to deliver the right portfolio as part of our growth strategy.

"As the number one generics company in the world, we can quickly bring a range of high-quality, cost-effective generic injectable treatments to patients within the doctor’s office, hospital, or clinic."

In the US, Lovenox had annual sales of about $1.8bn as of November 2014 and Zyvox Injection had annual sales of around $464m as of October 2014, according to IMS data.

Image: Teva Pharmaceutical introduces generic equivalent of Lovenox injection and Zyvox injection in US. Photo: courtesy of Baitong333/ freedigitalphotos.net.